Key Takeaways
- Margin normalization, not distress: After enjoying abnormally wide margins a couple of years ago, the company is "back to the normal," with management confident it can defend current levels because competitors face the same raw material cost consequences.
- Volume resilience masked by price-led top-line decline: The QoQ revenue drop was largely value-driven (lower prices from raw material stabilization and competition), while volumes were more or less flat; H1 year-on-year volume grew despite losing COVID-related medicine volumes.
- Pharma drag easing, agrochemicals strong: Three Pharma headwinds (inventory build-up, export difficulties, China supply chain issues) are slowly sorting out, while the agrochemical industry is doing quite well on domestic and export demand.
- New product pipeline is the growth thesis: Five to six import-substitute products, developed in-house with no launches in the last four years, are expected to add 20–25% of top line at full capacity and contribute significantly to the bottom line, with the first launch by end of this year.
- What to watch next quarter: Whether the first new product actually ships by December, whether Pharma's hoped-for H2 upturn materializes, and whether ammonia and coal costs continue easing or stay elevated.
Demand Environment & End-Market Health
- Pharma: three problems unwinding slowly: Inventory build-up, export difficulties, and China supply chain issues all hit the industry simultaneously; management sees these gradually sorting out and hopes for a better H2, though the cautionary note is that unexpected things can happen.
- Agrochemicals: a bright spot: The industry appears to be doing quite well, driven by domestic needs and export markets; products like Isopropylamine feed into Glyphosate, and some new capacities coming up may help further.
- Volume growth despite headwinds: H1 year-on-year volume grew even after losing volumes from COVID-related medicine products that are no longer being supplied; Pharma is returning to normal but had inventories to run down first.
- Acetonitrile market softness: The Indian market may have seen small degrowth because Pharma had problems; recycled waste acetonitrile entering India and being used by some industries, including Pharma, is affecting tonnages, and this is "something which is not going to stop."
Yogesh Kothari: "Even though industries are not supposed to use, like the Pharma industry and all, apparently, some of them are using it, you know, which is to some extent affecting tonnages. But it is something which is not going to stop."
Revenue & Volume Dynamics
- Price-driven top-line decline: The QoQ revenue decline is largely value-driven because raw material prices stabilized and partly due to competition; volumes were more or less flat quarter-on-quarter.
- H1 split confirms the pattern: About one-third of H1 year-on-year top-line growth came from volume and two-thirds from price, reflecting the pass-through of elevated raw material costs earlier in the cycle.
- Management declines to quantify volumes: When asked for specific volume growth numbers for Q2 and H1, management stated, "We don't talk about specific volume... We don't give exact numbers," offering only directional indications.
- Long-term volume CAGR under pressure this year: The company has achieved 10–15% volume growth CAGR more or less over the last 10 years; this year will be on the lower side of that estimate and "looks a bit of a struggle given the environment right now."
Kirat Patel: "At the last Con-Call, we had indicated that we look at a long term period for 10% to 15% growth, which we have more or less achieved in the last 10 years. However, this year I don't think we will be able to. We may be on the lower side of this estimate. And it looks bit of a struggle given the environment right now."
Margins & Cost Structure
- Back to normal after a super-cycle: A couple of years ago the company enjoyed a very wide increase in margins; management states plainly that "we are now back to the normal" and believes current margins are defensible because competitors face the same raw material price consequences.
- Ammonia: the standout cost pain: Ammonia prices have hit the company "in quite a significant way," with the Europe conflict driving the cost to some extent; management hopes the conflict ends fast.
- Power cost mitigation underway: The company is adding solar capacity and deploying high-temperature boilers with a turbine to generate more power internally, both of which will contribute to bringing down electricity cost.
- Raw material trajectory mixed: Prices of some raw materials have started coming down, but some are still at high rates; the Europe conflict has added to cost increases in some areas.
- No pricing power, market sets the price: Management is explicit that price is decided by the market and competition; capacities exist in the country and markets have not grown as fast as expected in some products, creating pressures until markets catch up.
Kirat Patel: "A couple of years ago, we had enjoyed a very wide increase in margins, and we are now back to the normal."
New Products & Capacity Expansion
- First launch in four years imminent: Hardly any new products have been launched in the last four years; the first new product, not made from any amine, is likely to start sometime by end of December 2022, with remaining products rolling out over the next 18–24 months at a pace of one or two every quarter or six months.
- Revenue ambition at full capacity: The sales potential at full capacity of these five to six products, three to four years down the line when full asset utilization is achieved, could be between ₹600 to 800 crores on the top line, though the market opportunity is much bigger.
- Import substitution with high barriers: Products are chosen where no more than one or two other producers exist; the stated ambition is to be among the top three producers in the world.
- Product mix and market focus: Most new products are not amine derivatives; one or two are export-oriented while the rest are domestically focused.
- Ethylamine expansion on track: The current ethylamine expansion will be finished by May/June 2023; the market is expected to see steady growth on the back of Pharma doing well, with mostly domestic sales and a bit of exports.
- Kurkumbh aliphatic amines plant: The ₹400 crore plant is on schedule and well within budget, with mechanical completion planned around April and commissioning by May end/June 2023.
- Payback discipline: New products carry higher payback expectations because risks are higher; existing products can accept longer payback because the market is known and risks are lower; minimum ROCE expectation is 20–25%.
Kirat Patel: "We would like to be among the top three producers in the world, you know."
Competitive & Market Dynamics
- Acetonitrile: steady but not at peak: Prices are reasonably steady after some pressure a quarter ago that now seems to be easing off, but they are not at the levels of a year and a half ago; raw material acetic acid has been stable and come down to reasonable levels.
- Recycled acetonitrile a structural irritant: Waste acetonitrile coming into India and being used by some industries, including Pharma, is affecting virgin material tonnages; management acknowledges this is "something which is not going to stop."
- Capacity ahead of demand in some products: Markets have not grown as fast as expected in some products, creating competitive pressures until markets catch up; management is trying to defend a certain set of margins and hopes the market will sensibly settle to a reasonable price and cost equation.
- Europe conflict: limited opportunity seen: Management does not see too much opportunity from Europe disruption currently, though there is always a possibility if the conflict drags on for more time.
- New methylamine plant planned: A new methylamine plant will be added after some time; the existing methylamine plant was an outlier, debottlenecked in just three years versus the normal five to seven years expected for a plant.
- DMF: a maybe, not a commitment: In principle the company has a plan for Dimethylformamide and at some stage perhaps will get into making it; it is one of the listed products in their environmental clearance application, but no timeline was given.
Kirat Patel: "Who decides the price? As we keep saying, the price is decided by the market, and the market is decided by the competition. So, it's very rare that, unless you are a monopoly, you will get the chance to decide this."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| First new product launch | First product (not made from any amine) to start production | By end December 2022 |
| Remaining new products rollout | One or two products every quarter or six months | Over 18–24 months from Q3 FY23 |
| Ethylamine expansion completion | Current expansion finished | May/June 2023 |
| Kurkumbh aliphatic amines plant | Mechanical completion April; commissioning May end/June 2023; on schedule, within budget | May/June 2023 |
| Long-term volume growth CAGR | 10–15% (achieved over last 10 years); this year on the lower side | FY23 as a transition year; resumption when environment settles |
| New product revenue contribution | Five/six products to add 20–25% of top line at full capacity (₹600–800 Cr sales potential) | 3–4 years from launch for full asset utilization |
| Minimum ROCE threshold | 20–25% across projects; higher for new products, lower acceptable for existing | Ongoing investment criterion |
| Margin defense | Trying to defend current normalized margins; market to settle to reasonable price/cost equation | No specific timeline; "very difficult to predict" |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | Volume more or less flat QoQ; top-line decline largely value-driven due to price drops |
| H1 FY23 top-line growth split | About one-third volume, about two-thirds price |
| Overall capacity utilization | Between 70%–80% |
| Ethylamine expansion capacity addition | 100 tons per day, commissioning by May/June 2023 |
| Aliphatic amines plant investment | Around ₹400 crores, commissioning May end/June 2023 |
| New products planned capacity (excl. ethylamine) | 25,000 to 30,000 tons aggregating across five/six products |
| New products revenue potential (excl. ethylamine) | ₹600 to 800 crores at full capacity, 3–4 years out |
| New products contribution prediction | Almost 20–25% of top line going forward |
| Long-term volume growth guidance | 10% to 15% CAGR; current year likely on lower side, a struggle |
| Existing methylamine capacity | ~200 tons per day (Dahej ~150 tpd, Patalganga 50 tpd) |
| Existing ethylamine capacity | 75 tons per day (Kurkumbh 50 tpd, Patalganga 25 tpd) |
| Acetonitrile total capacity | 28,000 to 30,000 tons (Kurkumbh ~12,000 tons, Dahej 16,000–18,000 tons) |
| Indian acetonitrile market size | ~28,000 to 30,000 tons last year, may have had small degrowth |
| Return on capital employed | Between 20% and 25% over a 10-year or last 5-year period |